Tenax Therapeutics Inc. Common Stock (TENX)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Tenax at $1.60 as of 2026-10-13, a $59.9 million market value. The company is a 14-employee, development-stage cardiopulmonary drug developer. In the filed figures, it reports no revenue, and the losses are substantial. In fiscal 2025, the year ended 2025-12-31, net income was -$52.6 million and diluted EPS was -$1.34. That was worse than fiscal 2024's -$17.6 million and -$1.15, and fiscal 2023's -$7.7 million. The first half of fiscal 2026 continued the burn: fiscal Q1 2026, ended 2026-03-31, lost $15.7 million; fiscal Q2 2026, ended 2026-06-30, lost $17.8 million. Trailing free cash flow is -$46.0 million, a FairStock FCF yield of -76.9%, so cash is going out fast. Financial health is poor by the numbers: FairStock's Piotroski F-Score is 1/9 and Altman Z-Score is 0.96, both pointing to distress. ROE is -59.80% and ROCE is -37.70% as FairStock calculations. The P/B of 0.73 might suggest a discount to book, but with negative returns and cash consumption, book value may not be durable. P/E of -1.08 simply reflects losses. FairStock Score 16/100 and Lynch TURNAROUND category—loss in latest year after earlier profits—fit a speculative clinical story, not a Buffett-style moat. The 52-week range of $1.31-$19.40 shows violent sentiment. A drug developer's only true moat is approved, protected, cash-generating medicine. Tenax has candidates but no revenue in these figures. I would demand proof of financing, trial progress, and a path to cash flow before calling the price cheap.

In plain English: Tenax Therapeutics is a small healthcare company trying to develop new medicines for heart and lung conditions. It has no product sales in the figures provided, it is losing money, and its losses have grown recently. The stock price looks low compared with the value of its reported assets minus liabilities, but the company is spending cash quickly, so cheapness here comes with a lot of risk.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer